Scancell Holdings plc
OTC: SCNLF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Phillip John L'Huillier
- Employees
- 61
- Headquarters
- Oxford, United Kingdom
- IPO year
- 2013
- Market cap
- $286.6M
- Website
- https://www.scancell.co.uk
Loading SCNLF…
Loading profile data…Frequently asked questions about SCNLF
What does Scancell Holdings plc (SCNLF) do?
Scancell Holdings plc is a biopharmaceutical company in the clinical development stage, focused on creating novel vaccines and antibody-based treatments. Its mission is to tackle significant unmet medical needs in both cancer and infectious diseases. The firm's developing therapies include SCIB1, an ImmunoBody cancer vaccine specifically for met...
Where does SCNLF trade?
Scancell Holdings plc (SCNLF) trades on the Other OTC.
What sector is SCNLF in?
Scancell Holdings plc (SCNLF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Scancell Holdings plc?
Phillip John L'Huillier is the chief executive officer of Scancell Holdings plc (SCNLF).
Where is Scancell Holdings plc headquartered?
Scancell Holdings plc is headquartered in United Kingdom.
Does SCNLF pay a dividend?
Scancell Holdings plc (SCNLF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SCNLF go public?
Scancell Holdings plc (SCNLF) completed its initial public offering in 2013.